{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '10.', 'ADVERSE EVENTS', '10.1.', 'Monitoring, Recording and Reporting of Adverse Events', 'An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen', 'in a subject during the course of a study. It may be a new intercurrent illness, a worsening', \"concomitant illness, an injury, or any concomitant impairment of the subject's health, including\", 'laboratory test values (as specified by the criteria in Section 10.3), regardless of etiology. Any', 'worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-', 'existing condition) should be considered an AE. A diagnosis or syndrome should be recorded on', 'the AE/SAE page of the eCRF rather than the individual signs or symptoms of the diagnosis or', 'syndrome.', 'Abuse, withdrawal, sensitivity, or toxicity to an investigational product should be reported as an', 'AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be', 'reported on the overdose eCRF. (See Section 7.7 for definition of overdose.) Any sequela of an', 'accidental or intentional overdose of an investigational product should be reported as an AE on', 'the AE eCRF. If the sequela of an overdose is a serious adverse event (SAE), then the sequela', 'must be reported on the paper SAE report form and on the AE eCRF. The overdose resulting in', 'the SAE should be identified as the cause of the event on the paper SAE report form and eCRF,', 'but should not be reported as an SAE itself.', 'In the event of overdose, the subject should be monitored as appropriate and should receive', 'supportive measures as necessary. There is no known specific antidote for apremilast overdose.', 'Actual treatment should depend on the severity of the clinical situation and the judgment and', 'experience of the treating physician.', 'All subjects will be monitored for AEs during the study. Assessments may include monitoring of', \"any or all of the following parameters: the subject's clinical symptoms; laboratory, pathological,\", 'radiological, or surgical findings; physical examination findings; or findings from other tests', 'and/or procedures.', 'All AEs will be recorded by the Investigator from the time the subject signs informed consent', 'until 28 days after the last dose of IP as well all SAEs made known to the Investigator at any', 'time following the protocol-required reporting period or after end of study. All adverse events', '(serious/non-serious) will be recorded on the eCRF, the paper SAE report form (for SAEs) and in', \"the subject's source documents. All SAEs must be reported to Amgen Global Patient Safety\", \"within 24 hours of the Investigator's knowledge of the event by recording on the eCRF\", 'submitting the SAE information using the paper Serious Adverse Event Report Form by', 'facsimile/email directly to Amgen Global Patient Safety.', '10.2.', 'Evaluation of Adverse Events', 'A qualified Investigator will evaluate all adverse events as to:', '10.2.1.', 'Seriousness', 'A serious adverse event (SAE) is any AE occurring at any dose that:', 'Results in death;', 'Confidential and Proprietary', '51', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate', 'risk of death from the AE);', 'Requires inpatient hospitalization or prolongation of existing hospitalization', '(hospitalization is defined as an inpatient admission, regardless of length of stay);', 'Results in persistent or significant disability/incapacity (a substantial disruption of the', \"subject's ability to conduct normal life functions);\", 'Is a congenital anomaly/birth defect;', 'Constitutes an important medical event.', 'Important medical events are defined as those occurrences that may not be immediately', 'life-threatening or result in death, hospitalization, or disability, but may jeopardize the subject or', 'require medical or surgical intervention to prevent one of the other outcomes listed above.', 'Medical and scientific judgment should be exercised in deciding whether such an AE should be', 'considered serious.', 'Events not considered to be SAEs are hospitalizations for:', 'A standard procedure for protocol therapy administration. However, hospitalization', 'or prolonged hospitalization for a complication of therapy administration will be', 'reported as an SAE.', 'Routine treatment or monitoring of the studied indication not associated with any', 'deterioration in condition.', 'The administration of blood or platelet transfusion as routine treatment of studied', 'indication. However, hospitalization or prolonged hospitalization for a complication', 'of such transfusion remains a reportable SAE.', 'A procedure for protocol/disease-related investigations (eg, surgery, scans,', 'endoscopy, sampling for laboratory tests, bone marrow sampling). However,', 'hospitalization or prolonged hospitalization for a complication of such procedures', 'remains a reportable SAE.', 'Hospitalization or prolongation of hospitalization for technical, practical, or social', 'reasons, in absence of an AE.', 'A procedure that is planned (ie, planned prior to start of treatment on study); must be', 'documented in the source document and the eCRF. Hospitalization or prolonged', 'hospitalization for a complication from such a procedure remains a reportable SAE.', 'An elective treatment of, or an elective procedure for, a pre-existing condition', 'unrelated to the studied indication, that has not worsened from baseline.', 'Emergency outpatient treatment or observation that does not result in admission,', 'unless fulfilling other seriousness criteria above.', 'If an AE is considered serious, both the AE page/screen of the eCRF and the paper SAE Report', 'Form must be completed. All SAEs must be reported to Amgen Global Patient Safety within 24', \"hours of the investigator's knowledge of the event by submitting the SAE information using the\", 'Confidential and Proprietary', '52', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'paper Serious Adverse Event Report Form by facsimile/email directly to Amgen Global Patient', 'Safety.', 'For each SAE, the Investigator will provide information on severity, start and stop dates,', 'relationship to the IP, action taken regarding the IP, and outcome.', '10.2.2.', 'Severity / Intensity', 'For both AEs and SAEs, the Investigator must assess the severity/intensity of the event', 'according to the following grading scale:', 'Mild', 'Asymptomatic or mild symptoms; clinical or diagnostic observations only', 'Intervention not indicated', 'Activities of Daily Living (ADLs) minimally or not affected', 'No or minimal intervention/therapy may be required', 'Moderate', 'Symptom(s) cause moderate discomfort', 'Local or noninvasive intervention indicated', 'More than minimal interference with ADLs but able to carry out daily social and', 'functional activities.', 'Drug therapy may be required', 'Severe (could be non-serious or serious)', 'Symptoms causing severe discomfort/pain', 'Symptoms requiring medical/surgical attention/intervention', 'Interference with AEs including inability to perform daily social and functional', 'activities (eg, absenteeism and/or bed rest)', 'Drug therapy is required', 'The term \"severe\" is often used to describe the intensity of a specific event (as in mild, moderate,', 'or severe myocardial infarction); the event itself, however, may be of relatively minor medical', 'significance (such as severe headache). This criterion is not the same as \"serious\", which is', 'based on subject/event outcome or action criteria associated with events that pose a threat to a', \"subject's life or functioning.\", 'Seriousness, not severity, serves as a guide for defining regulatory obligations.', '10.2.3.', 'Causality', 'The Investigator must determine the relationship between the administration of IP and the', 'occurrence of an AE/SAE as Not Suspected or Suspected as defined below:', 'Confidential and Proprietary', '53', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}